GlassScriptPhysician profile
Rayleene Miranda
NPI 1316762768
$2,643.36
in general payments reported to CMS, 2019-2025
17 companies · $2,643 in 2025
The $2,643 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.94 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $945.13 | 2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $283.35 | 2025 | Valtoco |
| Lundbeck LLC | $228.30 | 2025 | Vyepti |
| Csl Behring | $212.08 | 2025 | Hizentra |
| Abbvie INC. | $196.32 | 2025 | |
| Amgen INC. | $131.09 | 2025 | Repatha |
| Supernus Pharmaceuticals, INC. | $124.25 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $96.91 | 2025 | Xelstrym |
| Acadia Pharmaceuticals INC | $87.62 | 2025 | Daybue |
| Corium, LLC | $63.63 | 2025 | Azstarys |
| Tris Pharma INC | $55.61 | 2025 | Dyanavel Xr |
| Biogen, INC. | $55.51 | 2025 | Spinraza, Vumerity |
| Novartis Pharmaceuticals Corporation | $49.08 | 2025 | |
| Jazz Pharmaceuticals INC. | $45.66 | 2025 | |
| Collegium Pharmaceutical, INC. | $34.82 | 2025 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $17.58 | 2025 | Tanlor |
| Neos Therapeutics, LP | $16.42 | 2025 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayleene Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.